News

Public · Published

Astellas and Audax Biosciences Enter Exclusive Option and License Agreement for DAX-044, a Novel Immune-Targeted IL-12 Antibody-Cytokine Fusion for Immuno-Oncology

Astellas and Audax Biosciences signed an exclusive option and license agreement for DAX-044, an immune-targeted IL-12 antibody-cytokine fusion for immuno-oncology. The deal gives Astellas an option to obtain a worldwide license. Total potential transaction value is up to US$1.34 billion, excluding royalties.

Published:

Updated:

What happened

Astellas and Audax Biosciences signed an exclusive option and license agreement for DAX-044, an immune-targeted IL-12 antibody-cytokine fusion for immuno-oncology. The deal gives Astellas an option to obtain a worldwide license. Total potential transaction value is up to US$1.34 billion, excluding royalties.

Confirmed

Global impact / market context

A deal worth up to US$1.34 billion signals that Astellas is willing to pay for early-stage cancer research rather than build it alone. For Audax, the money supports development into Phase 1 testing, which means the first stage of testing in people.

Analyst inference

Large drugmakers often pay for options on experimental treatments before costly human trials, spreading risk while securing future growth. This agreement adds an early cancer candidate to Astellas' pipeline. Its value depends on the option being exercised and on Phase 1 results.

Analyst inference

What to watch

  1. Audax will fund and continue DAX-044 development into Phase 1, the first stage of testing in people. Confirmed
  2. Watch whether Astellas exercises its exclusive option, which would trigger a worldwide license to develop, manufacture and commercialize DAX-044. Proposed
  3. Track Phase 1 progress, since the up to US$1.34 billion total excludes royalties and likely depends on milestones being met. Analyst inference

Evidence

  • Original source link unavailable